WO1999006552A3 - 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN - Google Patents

5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN Download PDF

Info

Publication number
WO1999006552A3
WO1999006552A3 PCT/IB1998/001236 IB9801236W WO9906552A3 WO 1999006552 A3 WO1999006552 A3 WO 1999006552A3 IB 9801236 W IB9801236 W IB 9801236W WO 9906552 A3 WO9906552 A3 WO 9906552A3
Authority
WO
WIPO (PCT)
Prior art keywords
ests
secreted proteins
brain
proteins expressed
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001236
Other languages
French (fr)
Other versions
WO1999006552B1 (en
WO1999006552A2 (en
Inventor
Milne Edwards Jean-Bapti Dumas
Aymeric Duclert
Bruno Lacroix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to AU85555/98A priority Critical patent/AU8555598A/en
Priority to CA002296667A priority patent/CA2296667A1/en
Priority to JP2000505293A priority patent/JP2001512015A/en
Priority to EP98936594A priority patent/EP1000150B1/en
Priority to DE69834190T priority patent/DE69834190T2/en
Publication of WO1999006552A2 publication Critical patent/WO1999006552A2/en
Publication of WO1999006552A3 publication Critical patent/WO1999006552A3/en
Publication of WO1999006552B1 publication Critical patent/WO1999006552B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors.
PCT/IB1998/001236 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN Ceased WO1999006552A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU85555/98A AU8555598A (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in brain
CA002296667A CA2296667A1 (en) 1997-08-01 1998-07-31 5' ests for secreted proteins expressed in brain
JP2000505293A JP2001512015A (en) 1997-08-01 1998-07-31 5 'EST of secreted proteins in the brain
EP98936594A EP1000150B1 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN
DE69834190T DE69834190T2 (en) 1997-08-01 1998-07-31 5 'ESTS FOR SECRETED PROTEINS EXPRESSED IN THE BRAIN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/905,223 US6222029B1 (en) 1997-08-01 1997-08-01 5′ ESTs for secreted proteins expressed in brain
US08/905,223 1997-08-01

Publications (3)

Publication Number Publication Date
WO1999006552A2 WO1999006552A2 (en) 1999-02-11
WO1999006552A3 true WO1999006552A3 (en) 1999-04-22
WO1999006552B1 WO1999006552B1 (en) 1999-06-03

Family

ID=25420448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001236 Ceased WO1999006552A2 (en) 1997-08-01 1998-07-31 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN

Country Status (8)

Country Link
US (1) US6222029B1 (en)
EP (1) EP1000150B1 (en)
JP (1) JP2001512015A (en)
AT (1) ATE323161T1 (en)
AU (1) AU8555598A (en)
CA (1) CA2296667A1 (en)
DE (1) DE69834190T2 (en)
WO (1) WO1999006552A2 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2281952C (en) 1997-02-25 2011-07-19 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6613872B1 (en) 1997-02-25 2003-09-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7119190B2 (en) 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2248971A1 (en) * 1997-10-31 1999-04-30 Kyowa Hakko Kogyo Co., Ltd. .beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use
US6548633B1 (en) 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides
US7045612B2 (en) 1998-01-16 2006-05-16 Mcgill University Human methionine synthase reductase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
AU3648499A (en) * 1998-04-17 1999-11-08 Emory University Protein phosphatase methylesterase dna
AU2006202355B2 (en) * 1998-05-01 2009-08-20 Glaxosmithkline Biologicals Sa Neisseria meningitidis antigens and compositions
US6096526A (en) 1998-05-20 2000-08-01 Incyte Pharmaceuticals, Inc. Human nucleic acid methylases
US6825328B1 (en) * 1998-07-20 2004-11-30 Stephen W. Scherer Lafora's disease gene
JP2002522016A (en) * 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Protein similar to neuroendocrine-specific protein and cDNA encoding the same
WO2000011163A1 (en) * 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
US7109292B2 (en) * 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU782985B2 (en) * 1999-04-09 2005-09-15 Curagen Corporation Novel human proteins and polynucleotides encoding them
JP2001269184A (en) * 1999-06-28 2001-10-02 Takeda Chem Ind Ltd New protein and dna encoding the same
US6682917B1 (en) 1999-06-28 2004-01-27 Takeda Chemical Industries, Ltd Protein having a ribonucleotide Reductase activity and a DNA thereof
EP1204746B1 (en) * 1999-07-31 2004-11-03 Board of Regents, The University of Texas System Sentrin-specific human protease senp1
ES2189560B1 (en) * 1999-10-01 2005-01-01 Consejo Superior De Investigaciones Cientificas DNA POLYMERASE K, NEW TUMOR MARKER.
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors
AU2001252585A1 (en) * 2000-04-28 2001-11-26 Takeda Chemical Industries Ltd. Novel g protein-coupled receptor protein and dna thereof
JP2004523201A (en) * 2000-05-16 2004-08-05 ザ チルドレンズ マーシー ホスピタル Single copy genome hybridization probe and method for producing the same
US6828097B1 (en) * 2000-05-16 2004-12-07 The Childrens Mercy Hospital Single copy genomic hybridization probes and method of generating same
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7202335B2 (en) * 2001-12-06 2007-04-10 Genentech, Inc. PRO300 polypeptides
EP1571970B1 (en) * 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
KR20170038128A (en) 2003-05-15 2017-04-05 앰피오 파마슈티컬스 인코퍼레이티드 Treatment of t-cell mediated diseases
WO2004111085A1 (en) * 2003-06-10 2004-12-23 Xantos Biomedicine Ag Angiogenic factor and its medical use
US7410772B2 (en) * 2004-07-02 2008-08-12 Genentech, Inc. Compositions and methods for treatment of non-Hodgkin's lymphoma
WO2008097467A1 (en) * 2007-02-02 2008-08-14 University Of Vermont And State Agricultural College Anti-methylation-controlled j protein antibodies and uses thereof
US8217047B2 (en) * 2008-05-27 2012-07-10 Dmi Acquisition Corp. Therapeutic methods and compounds
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
EA028343B1 (en) 2011-10-10 2017-11-30 Ампио Фармасьютикалз, Инк. Treatment of degenerative joint disease
CN103841974A (en) 2011-10-28 2014-06-04 安皮奥制药股份有限公司 Treatment of rhinitis
US10583169B2 (en) 2012-07-11 2020-03-10 University Of Vermont And State Agricultural College Methylation-controlled J protein (MCJ) for treatment of liver disease and altering mitochondrial metabolism
MX2015010937A (en) 2013-03-15 2015-10-29 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same.
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
CN107592866A (en) 2015-02-18 2018-01-16 佛蒙特大学及州农业学院 MCJ activators and application thereof
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CN108136005A (en) 2015-07-10 2018-06-08 佛蒙特大学及州农业学院 For the disease of medicine induction and the MCJ inhibitor of illness

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279582A2 (en) * 1987-02-17 1988-08-24 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279582A2 (en) * 1987-02-17 1988-08-24 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
EP0625572A1 (en) * 1992-09-25 1994-11-23 The Kanagawa Academy Of Science And Technology Foundation PROCESS FOR SYNTHESIZING COMPLETE-LENGTH cDNA, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING RECOMBINANT VECTOR CONTAINING COMPLETE-LENGTH cDNA
WO1996034981A2 (en) * 1995-05-02 1996-11-07 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE CAP OF THE EXTREMITY 5' OF A FRAGMENT mRNA AND PREPARATION OF mRNA AND COMPLETE cDNA
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ADAMS M D ET AL: "3,400 NEW EXPRESSED SEQUENCE TAGS IDENTIFY DIVERSITY OF TRANSCRIPTS IN HUMAN BRAIN", NATURE GENETICS, vol. 4, no. 3, July 1993 (1993-07-01), pages 256 - 267, XP000645060 *
ADAMS M D ET AL: "RAPID CDNA SEQUENCING (EXPRESSED SEQUENCE TAGS) FROM A DIRECTIONALLY CLONED HUMAN INFANT BRAIN CDNA LIBRARY", NATURE GENETICS, vol. 4, no. 4, August 1993 (1993-08-01), pages 373 - 380, STANDARD, XP002064427 *
CARNINCI P. ET AL.: "High-efficiency full-length cDNA cloning by biotinylated CAP trapper", GENOMICS, vol. 37, no. 3, 1 November 1996 (1996-11-01), pages 327 - 336, XP002081729 *
DATABASE EMBL - R55U017 22 August 1996 (1996-08-22), LLOYD, D.: "Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 181C9", XP002083782 *
GREENWOOD M T ET AL: "Cloning of the gene encoding human somatostatin receptor 2: sequence analysis of the 5@?-flanking promoter region", GENE, vol. 159, no. 2, 4 July 1995 (1995-07-04), pages 291-292, XP004042228 *
HEIJNE VON G.: "A new method for predicting signal sequence cleavage sites", NUCLEIC ACIDS RESEARCH, vol. 14, no. 11, 1986, pages 4683 - 4690, XP002053954 *
KATO S. ET AL.: "Construction of a human full-length cDNA bank", GENE, vol. 150, 1994, pages 243 - 250, XP002081364 *
LIN Y ET AL: "INHIBITION OF NUCLEAR TRANSLOCATION OF TRANSCRIPTION FACTOR NF-KB BY A SYNTHETIC PEPTIDE CONTAINING A CELL MEMBRANE-PERMEABLE MOTIF AND NUCLEAR LOCALIZATION SEQUENCE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 24, 16 June 1995 (1995-06-16), pages 14255 - 14258, XP002050723 *
LOCKHART D J ET AL: "EXPRESSION MONITORING BY HYBRIDIZATION TO HIGH-DENSITY OLIGONUCLEOTIDE ARRAYS", BIO/TECHNOLOGY, vol. 14, no. 13, December 1996 (1996-12-01), pages 1675 - 1680, XP002022521 *
TASHIRO K. ET AL.: "Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins", SCIENCE, vol. 261, 30 July 1993 (1993-07-30), pages 600 - 603, XP000673204 *
YOKOYAMA-KOBAYASHI M. ET AL.: "A signal sequence detection system using secreted protease activity as an indicator", GENE, vol. 163, 1995, pages 193 - 196, XP002053953 *

Also Published As

Publication number Publication date
ATE323161T1 (en) 2006-04-15
US6222029B1 (en) 2001-04-24
WO1999006552B1 (en) 1999-06-03
EP1000150B1 (en) 2006-04-12
AU8555598A (en) 1999-02-22
JP2001512015A (en) 2001-08-21
WO1999006552A2 (en) 1999-02-11
DE69834190T2 (en) 2007-01-11
EP1000150A2 (en) 2000-05-17
CA2296667A1 (en) 1999-02-11
DE69834190D1 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
WO1999006552A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN BRAIN
WO1999006550A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
WO1999006548A3 (en) 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
WO1999053051A3 (en) 5' ests and encoded human proteins
WO1999006554A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES
WO1999006549A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN TESTIS AND OTHER TISSUES
EP1033401A3 (en) Expressed sequence tags and encoded human proteins
WO1999006551A3 (en) 5' ESTs FOR SECRETED PROTEINS IDENTIFIED FROM BRAIN TISSUES
WO1999006439A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM
WO1999006553A3 (en) 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN VARIOUS TISSUES
WO1999031236A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999025825A3 (en) EXTENDED cDNAs FOR SECRETED PROTEINS
WO1999040189A3 (en) Cdnas encoding secreted proteins
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
CA2200371A1 (en) Human npik gene
CA2253238A1 (en) Novel agouti-related gene
WO1998031800A3 (en) Human proteins
WO2000058339A3 (en) 50 human secreted proteins
WO2000043495A3 (en) 33 human secreted proteins
WO1999054446A3 (en) Human nucleic acid sequences which are overexpressed in normal pancreas tissue
EP1903111A3 (en) Extended cDNAs for secreted proteins
AU7433696A (en) Tyrosine kinase associated protein-1 (tka-1), nucleotide and amino acid sequences and their use in diagnosis and treatment of tka-1 related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2296667

Country of ref document: CA

Ref country code: CA

Ref document number: 2296667

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 85555/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998936594

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998936594

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1998936594

Country of ref document: EP